Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Biogen Idec Inc.
IndexS&P 500 P/E28.85 EPS (ttm)10.57 Insider Own0.10% Shs Outstand236.16M Perf Week0.43%
Market Cap72.01B Forward P/E18.72 EPS next Y16.29 Insider Trans2.16% Shs Float235.94M Perf Month-4.12%
Income2.51B PEG1.41 EPS next Q3.76 Inst Own92.10% Short Float1.14% Perf Quarter-10.64%
Sales9.03B P/S7.98 EPS this Y35.60% Inst Trans-0.25% Short Ratio1.96 Perf Half Y-4.52%
Book/sh44.14 P/B6.91 EPS next Y20.53% ROA19.80% Target Price371.24 Perf Year5.44%
Cash/sh7.88 P/C38.69 EPS next 5Y20.40% ROE26.60% 52W Range270.27 - 358.89 Perf YTD9.07%
Dividend- P/FCF27.50 EPS past 5Y24.10% ROI20.70% 52W High-15.04% Beta1.13
Dividend %- Quick Ratio1.90 Sales past 5Y11.10% Gross Margin87.50% 52W Low12.82% ATR7.86
Employees6850 Current Ratio2.30 Sales Q/Q37.40% Oper. Margin37.70% RSI (14)41.21 Volatility1.58% 2.12%
OptionableYes Debt/Eq0.06 EPS Q/Q76.60% Profit Margin27.80% Rel Volume0.80 Prev Close305.40
ShortableYes LT Debt/Eq0.06 EarningsOct 22 BMO Payout0.00% Avg Volume1.37M Price304.92
Recom2.10 SMA20-3.01% SMA50-4.25% SMA200-4.16% Volume1,085,830 Change-0.16%
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Mar-19-14Reiterated Stifel Buy $360 → $376
Mar-07-14Reiterated Barclays Overweight $325 → $352
Mar-03-14Reiterated Stifel Buy $330 → $360
Jan-30-14Reiterated UBS Neutral $300 → $310
Jan-30-14Reiterated Brean Capital Buy $293 → $377
Jan-30-14Reiterated Argus Buy $310 → $360
Jan-28-14Reiterated Deutsche Bank Buy $340 → $415
Jan-27-14Reiterated Canaccord Genuity Buy $291 → $355
Jan-16-14Reiterated Stifel Buy $296 → $321
Jan-10-14Reiterated Barclays Overweight $285 → $325
Dec-20-13Reiterated RBC Capital Mkts Outperform $275 → $325
Dec-12-13Reiterated Argus Buy $280 → $310
Oct-30-13Initiated FBR Capital Mkt Perform $259
Oct-29-13Reiterated Barclays Overweight $240 → $262
Jul-17-13Reiterated Barclays Overweight $220 → $240
Nov-26-14 04:00PM  Isis Pharmaceuticals Earns Milestone on Study Initiation Zacks
09:54AM  Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval Zacks
Nov-25-14 01:18PM  Midday movers: Apple, Netflix, Comcast & more at CNBC
11:46AM  Biogens Tecfidera Label Updated After Rare Brain Infection Case at Bloomberg
06:18AM  Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% Zacks
Nov-24-14 03:20PM  Immunomedics' Veltuzumab Receives Orphan Drug Status Zacks
07:18AM  Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% Zacks
Nov-21-14 07:00AM  Finding a Margin of Safety in a Fully Valued Market Morningstar
Nov-20-14 03:33PM  Agios (AGIO) Shares Up on Positive AG-120 Study Data Zacks
07:54AM  Zacks Industry Outlook Highlights: Mylan, Sanofi, Amgen, Biogen, and Actavis Zacks
Nov-19-14 04:01PM  Biogen Idec to Present at the 2014 Deutsche Bank BioFEST Conference Business Wire
09:58AM  UPDATE: Credit Suisse Reiterates On Biogen Idec On Gilenya PPMS Risk Benzinga
07:35AM  Argos Therapeutics (ARGS) Jumps: Stock Gains 7.4% Zacks
Nov-18-14 04:30PM  Kite Pharma Gains on Positive Opinion for KTE-C19 Zacks
12:20PM  Actavis Strikes $66 Billion Deal for Botox Maker Allergan Zacks
07:17AM  Sunesis Pharmaceuticals (SNSS) Jumps: Stock Surges 38.3% Zacks
06:00AM  'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen at TheStreet
Nov-17-14 07:07PM  Lightning Round: Wal-Mart is better than this at CNBC
06:00PM  Cramer: This stock has begun to turnaround CNBC
05:40PM  Alnylam Reports Positive Initial Phase II Data on Revusiran Zacks
Nov-15-14 10:13AM  U.S. FDA approves Sanofi's MS drug Lemtrada Reuters
Nov-14-14 06:22PM  Biotech Stocks Hit: Stock Market To See New Leaders? at Investor's Business Daily
05:13PM  Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive Zacks
04:21PM  All in all, another solid week for U.S. equities... Yahoo Finance Blogs
03:30PM  Isis/AstraZeneca Expand Antisense Technology Collaboration Zacks
02:48PM  Stocks Drift Lower As Biotechs Tumble at Investor's Business Daily
01:32PM  Stocks Mixed; Amazon Jumps On Book Deal at Investor's Business Daily
08:05AM  Early Movers: BHI, HTZ, SBUX, HLF & more at CNBC
Nov-13-14 02:41PM  The Bull/Bear Breakdown On Biogen Idec Benzinga
11:15AM  Insider Trading Alert - RP, RLGY And BIIB Traded By Insiders at TheStreet
Nov-11-14 04:30PM  Dynavax's Heplisav Phase III Trial Recommended to Continue Zacks
08:31AM  Stock Market News for November 11, 2014 Zacks
06:38AM  Orexigen (OREX) Worth Watching: Stock Soars 33.3% Zacks
Nov-10-14 04:46PM  Shire CEO Looks Ahead To Independent Future at Investor's Business Daily
04:03PM  Intercept Pharmaceuticals' Shares Crash on FLINT Results Zacks
Nov-07-14 11:08AM  Medivation Q3 Earnings, Revenues Lag Estimates Zacks
10:09AM  Salix Q3 Earnings Marred by Inventory Issues, Cuts View Zacks
Nov-06-14 06:41PM  Top Large-Cap Growth Mutual Funds Defy Gravity at Investor's Business Daily
05:25PM  Vertex Pharmaceuticals Seeks Approval for CF Combination Zacks
01:57PM  Celldex Falls with Pipeline Update Overshadowing Q3 Results Zacks
11:40AM  Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus Zacks
Nov-05-14 04:10PM  Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? Zacks
01:20PM  Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance Zacks
Nov-04-14 08:14PM  These 5 Drugmakers' Earnings Excelled This Quarter at Investor's Business Daily
08:00AM  Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold Zacks
05:43AM  Is Biogen Idec (BIIB) a Great Growth Stock? Zacks
Nov-03-14 11:50AM  Seattle Genetics Gains on Narrower-than-Expected Q3 Loss Zacks
Oct-31-14 04:11PM  Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Authorisation Application for review Thomson Reuters ONE
04:05PM  Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA (rFVIIIFc) Marketing Authorization Application for Review Business Wire
02:30PM  Affymetrix Beats Q3 Earnings & Revenues; Raises '14 View Zacks
01:40PM  Incyte Gains on Q3 Earnings and Revenue Beat, Raises View Zacks
12:20PM  Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook Zacks
10:45AM  AMAG Up on Q3 Earnings Beat, Revenues Up Zacks
09:50AM  Today's Momo Momentum Stock To Watch: Biogen Idec (BIIB) at TheStreet
08:13AM  Incyte (INCY) Looks Good: Stock Moves 10.9% Higher Zacks
06:00AM  Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX at TheStreet
Oct-29-14 05:00PM  Amgens operating margins have been flat despite revenue growth Market Realist
01:04PM  BIOGEN IDEC INC. Financials EDGAR Online Financials
09:00AM  Third Point Partners ups stake in Amgen Market Realist
Oct-28-14 08:03PM  Top Holdings Of Top Health Care Funds: Alexion, Gilead, Celgene at Investor's Business Daily
03:10PM  Pfizer Q3 Earnings Top Estimates Despite Generic Pressure Zacks
08:10AM  Amgen Beats on Q3 Earnings & Revenues, Ups View Again Zacks
Oct-27-14 10:00AM  Merck Tops on Q3 Earnings, Patent Expiries Hit Revenues Zacks
09:40AM  Allergan Beats on Earnings, Revenues; Valeant Raises Offer Zacks
09:27AM  For A New Graduate Interested In A Drug R&D Job, Is Biotech Better Than Big Pharma? at Forbes
Oct-24-14 04:25PM  Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case Zacks
Oct-23-14 11:25AM  Citi, Jefferies Weigh In On Biogen Idec Amid Q3 Earnings Benzinga
10:35AM  Fidelity Biotech Fund Cut Biogen Stake Over Five Months at Bloomberg
07:30AM  Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases Business Wire
07:18AM  US STOCKS-Futures inch up, indicating rebound; earnings awaited Reuters
Oct-22-14 06:43PM  Biogen, Thermo Reports Disappoint; Abbott Accelerates at Investor's Business Daily -5.42%
05:18PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:43PM  Markets Reverse Early Morning Gains Following Canadian Shooting Benzinga
04:28PM  As earnings season heats up, stocks close on the lows Yahoo Finance Blogs
04:24PM  Major Indexes End Win Streak; Super Micro Surges at Investor's Business Daily
03:06PM  Stocks Erase Modest Gains; Apple Flirts With Breakout at Investor's Business Daily
01:24PM  Biogen Idec upgraded by Robert W. Baird
12:50PM  Dow Chemical rallies on strong earnings at Financial Times
12:39PM  Why Biogen Idec (BIIB) Stock Is Tanking Today at TheStreet
12:10PM  Biogen's Q3 Earnings Top Estimates, View Raised Again Zacks
09:52AM  Trade-Ideas: Biogen Idec (BIIB) Is Today's Unusual Social Activity Stock at TheStreet
09:05AM  Biogen Takes Breather on Earnings and MS Drug Sales at 24/7 Wall St.
08:30AM  Biogen Idec Inc Earnings Call scheduled for 8:30 am ET today CCBN
08:08AM  Biogen Falls as Top Drugs Sales Fail to Reach Estimates at Bloomberg
07:48AM  [$$] Biogen Idec Sales Surge 37% at The Wall Street Journal
07:24AM  Biogen beats Street 3Q forecasts AP
07:23AM  BIOGEN IDEC INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:15AM  Biogen shares rally after beating profit expectations, raising outlook at MarketWatch
07:07AM  Q3 2014 Biogen Idec Inc Earnings Release - Before Market Open CCBN
07:00AM  Biogen Idec Third Quarter 2014 Revenues Increase 37% to $2.5 Billion Business Wire
Oct-21-14 06:48PM  Boeing, AT&T reports due Wednesday; Yahoo up late at MarketWatch
06:47PM  Celgene Rises 8% In Two Days On Crohn's Disease Drug Data Investor's Business Daily
05:03PM  Yahoo, Super Micro Rally After Hours at Investor's Business Daily
11:32AM  Video: Celgene Reports More Good Crohn's Drug Data at Investor's Business Daily
Oct-20-14 03:45PM  Will Biogen Idec (BIIB) Pull a Surprise this Earnings Season? Zacks
02:51PM  Will High Price Hurt Gilead Sciences' New Hep-C Drug? at
11:50AM  Will Sangamo (SGMO) Incur Wider-than-Expected Q3 Loss? Zacks
11:16AM  Celgene's Crohn's Disease Drug Hits Its Marks at Investor's Business Daily
Oct-18-14 08:02AM  Celgene, Alexion Among 4 IBD 50 Medicals To Report at Investor's Business Daily
Oct-17-14 11:14AM  3 Stocks Reiterated As A Buy: VZ, WMT, BIIB at TheStreet
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn's disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company's products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM
Holtzman Steven HEVP Corporate DevelopmentApr 17Sale291.001,221355,3116,970Apr 21 05:07 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,677Apr 03 04:27 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale308.422,123654,77626,142Apr 02 04:16 PM
Posner Brian SDirectorMar 31Sale296.763,000890,2756,435Apr 01 04:15 PM
DORSA CAROLINEDirectorMar 20Option Exercise53.6410,000536,40024,468Mar 21 04:17 PM
DORSA CAROLINEDirectorMar 20Sale348.8810,0003,488,81314,468Mar 21 04:17 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentMar 19Sale352.293,5051,234,7767,976Mar 21 04:15 PM
Holtzman Steven HEVP Corporate DevelopmentMar 17Sale334.831,221408,8278,191Mar 18 05:08 PM
Kingsley Stuart AEVP, Global Comm. OperationsMar 11Sale336.838,4282,838,7663,511Mar 12 07:15 PM
SCANGOS GEORGE AChief Executive OfficerMar 10Sale333.7726,1248,719,37828,265Mar 12 07:20 PM
LEAMING NANCYDirectorMar 10Sale327.652,000655,3007,660Mar 12 07:16 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 04Sale342.583,1711,086,32115,407Mar 05 03:12 PM
SCANGOS GEORGE AChief Executive OfficerMar 03Sale335.792,942987,89454,389Mar 04 03:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 26Sale342.171,048358,59421,407Feb 27 04:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 23Option Exercise0.001,988023,395Feb 25 02:21 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 23Option Exercise0.002,598026,706Feb 25 02:17 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.004,280017,473Feb 25 02:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.003,821023,930Feb 25 02:07 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 18Sale327.901,222400,6949,412Feb 19 04:23 PM
DiPietro KennethEVP Human ResourcesFeb 13Sale316.811,290408,6850Feb 14 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 13Sale316.81486153,97057,331Feb 14 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 13Sale316.42425134,47821,407Feb 14 04:42 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.002,246012,998Feb 14 04:33 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.003,573013,166Feb 14 04:48 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.002,807014,517Feb 14 04:46 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.002,142021,119Feb 14 04:43 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.0071401,941Feb 14 04:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.00792014,459Feb 14 04:42 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.002,142011,644Feb 14 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.009,189062,150Feb 14 04:37 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.002,24602,246Feb 14 04:36 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.003150690Feb 14 04:38 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.002,246025,167Feb 14 04:34 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 11Sale314.312,085655,33613,667Feb 12 05:03 PM
SCANGOS GEORGE AChief Executive OfficerFeb 11Sale314.312,456771,94552,961Feb 12 05:00 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833064,297Feb 11 07:55 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691013,922Feb 11 07:49 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270050,314Feb 11 07:55 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,824011,613Feb 11 07:52 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909020,723Feb 11 06:07 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691025,133Feb 11 06:07 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,346Feb 11 07:43 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277014,944Feb 11 07:43 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023021,883Feb 11 06:07 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498017,633Feb 11 06:07 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,636011,032Feb 11 07:52 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191010,278Feb 11 07:49 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468011,229Feb 11 07:47 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,705010,778Feb 11 07:45 PM
DiPietro KennethEVP Human ResourcesFeb 04Sale299.011,655494,8620Feb 05 04:36 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 03 05:29 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,15909,730Feb 03 05:25 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 01Option Exercise0.004,586010,097Feb 03 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,159010,044Feb 03 05:15 PM
Rowinsky Eric KDirectorJan 21Sale310.092,020626,38210,440Jan 22 04:49 PM
YOUNG WILLIAMDirectorJan 08Sale285.1115,0004,276,59018,509Jan 09 04:24 PM
PANGIA ROBERT WDirectorJan 06Option Exercise47.556,250297,18820,253Jan 07 12:22 PM
PANGIA ROBERT WDirectorJan 06Sale278.036,2501,737,68814,003Jan 07 12:22 PM
SHERWIN STEPHEN ADirectorJan 02Option Exercise59.825,500329,0109,460Jan 06 11:19 AM
SHERWIN STEPHEN ADirectorJan 02Sale279.285,5001,536,0593,960Jan 06 11:19 AM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale285.90439125,51013,667Dec 05 02:53 PM
SCHENK LYNNDirectorDec 02Sale291.711,000291,7104,100Dec 02 03:28 PM